Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00296816
Status:
COMPLETED
Last Update Posted:
2012-08-23
First Post:
2006-02-23
Brief Title:
TEACO Taxotere Eloxatin Avastin in Cancer of the Ovary
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel With Bevacizumab as First Line Therapy in Patients With FIGO Stage IB-IV Epithelial Ovarian Primary Peritoneal or Fallopian Tube Carcinoma
Status:
COMPLETED
Status Verified Date:
2011-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEACO
Brief Summary:
Feasibility study to assess a novel combination of cytotoxic agents docetaxel and oxaliplatin as first-line therapy in the treatment of ovarian cancer and the impact of angiogenesis inhibition for the progression and prognosis of ovarian cancer by concurrent addition of bevacizumab Avastin
Detailed Description:
Participants were
administered study medication approximately 28 days after initial surgery for ovarian cancer
received the study treatment regimen of up to one year unless there was disease progression unacceptable toxicity death participant refusal or treatment delay beyond the time frame permitted for each treatment
Participants were followed for survival for a minimum 3 years from the date of enrollment
administered study medication approximately 28 days after initial surgery for ovarian cancer
received the study treatment regimen of up to one year unless there was disease progression unacceptable toxicity death participant refusal or treatment delay beyond the time frame permitted for each treatment
Participants were followed for survival for a minimum 3 years from the date of enrollment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None